Using the evidence in practice

I choose urinary Tract Infection as an acute and episodic condition.

Recently there is a new FDA warning regarding the use of Fluoroquinolone Antibacterial Drug. FDA recommends that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options. My preceptor made a decision to follow this guideline regarding the prescription of ATB for uncomplicated urinary tract infection.

According to the recommendation, treatment of choice for uncomplicated UTI is as:

First line treatment – 3 days of Sulfa or 5 to 7 days of Nitrofurantoin.

Second line treatment – 3 days of Quinolone (contraindicated in pregnancy) or 7 days of Amoxicillin.

I accessed the website by using word urinary tract infection in search and found this FDA recommendation/warning which I was already made aware last week during the encounter with a patient who diagnosed with urinary tract infection. This website is really a good source to learn about FDA approved recommendations regarding different diagnosis and treatments associated with them. I have seen some other recommendations which are currently used by my workplace but I was not sure why we do the things like this, my thinking was it’s a way to do things. It is a good source to enhance knowledge and to keep up to date with recent information. This guideline is going to be followed in my clinical setting.

Reference:

Specialty, B. C. (n.d.). Urinary tract infection. Retrieved September 25, 2016, from http://www.guideline.gov/summary/34419/urinary-tract-infection

Leave a comment